Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Irinotecan in Advanced Gastric Cancer
NCT03030937Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), esophagogastric junction adenocarcinoma (GEJA), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT03030937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030937.